Therapeutic Advances in Cardiovascular Disease

Therapeutic Advances in Cardiovascular Disease is an open access journal on the medical treatment of heart and circulatory conditions, published by SAGE.《Therapeutic Advances in Cardiovascular Disease》是一份聚焦心脏与循环系统疾病药物治疗的开放获取期刊，由 SAGE 出版。

It was launched in 2007 and carries clinically focused research on how treatment is chosen, delivered and improved.该刊于 2007 年创办，载有关于治疗如何被选择、实施与改进的临床取向研究。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3, and it stands in the second quartile of cardiac and cardiovascular systems.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在心脏与心血管系统类目列第二区。

Scope

• The journal takes the treatment of cardiovascular disease as its subject, and it asks how care along the whole pathway is improved.该刊以心血管疾病的治疗为题材，追问照护在整条路径上如何被改进。

• Pharmacological treatment is a central subject, and the journal carries work on how a drug is chosen and how it is dosed.药物治疗是核心选题，该刊刊载药物如何被选用、剂量如何确定的工作。

• Interventional strategies are named, and the journal admits work on how a procedure is performed and how its outcome is judged.介入策略被点名，该刊收载手术如何施行、其结果如何评判的工作。

• Preventive care is treated, and the journal takes work on how a risk is lowered before an event.预防性照护得到处理，该刊收载风险如何在事件发生之前被降低的工作。

• Hypertension is named, and the journal carries work on how raised blood pressure is managed over the long term.高血压被点名，该刊刊载升高的血压如何被长期管理的工作。

• Heart failure is part of the remit, and the journal admits work on how a failing heart is supported by treatment.心力衰竭属于收稿范围，该刊收载衰竭的心脏如何由治疗支撑的工作。

• Ischaemic heart disease is treated, and the journal takes work on how a blocked vessel is dealt with.缺血性心脏病得到处理，该刊收载阻塞的血管如何被处置的工作。

• Real world implementation is named, and the journal carries work on how a treatment performs outside a trial.真实世界实施被点名，该刊刊载治疗在试验之外如何表现的工作。

• Patient outcomes are weighed, and the journal asks what a treatment does for the person who receives it.患者结局受到权衡，该刊追问治疗为接受它的人做了什么。

• Service outcomes are named, and the journal admits work on how a care pathway is organised and delivered.服务结局被点名，该刊收载照护路径如何被组织与交付的工作。

• Systematic reviews are taken, and the journal carries work that draws the evidence of many studies into one view.系统综述受到收载，该刊刊载把多项研究的证据汇入一个视角的工作。

• Narrative reviews are admitted, and the journal gives room to a reading of a field by an experienced author.叙述性综述受到收载，该刊为资深作者对某一领域的解读留出篇幅。

• Consensus statements and guidelines are named, and the journal takes a reasoned statement of how a condition ought to be treated.共识声明与指南被点名，该刊收载关于某一病症应如何处理的可信陈述。

• Clinical pharmacology is part of the remit, and the journal admits work on how a drug acts and how it interacts.临床药理学属于收稿范围，该刊收载药物如何起作用、如何相互作用的工作。

• Precision medicine is named, and the journal carries work on how treatment is matched to a patient's make up.精准医学被点名，该刊刊载治疗如何与患者禀赋相匹配的工作。

• Scholarly comment is admitted, and the journal takes a short argument on how a finding ought to be read.学术评论受到收载，该刊收载关于某项发现应如何解读的短论。

History

• The journal was launched in 2007 by SAGE, and it has appeared as an electronic title from its first volume.该刊于 2007 年由 SAGE 创办，自首卷起便以电子刊物的形式出现。

• The pair of numbers has stayed with the title, and the print and electronic editions share the same strings of digits.该对刊号一直伴随题名，印本与电子版共用同样的数字串。

• A volume is published for each year, and the series had reached volume 19 by 2025.该刊每年出版一卷，到 2025 年已出至第 19 卷。

• The volume is no longer divided into issues, and articles are published continuously as each is ready.卷不再按期划分，论文随每篇就绪而连续发表。

• Access was open from the start, and every article is free to read from the moment it appears.该刊自始即开放获取，每篇文章自出现那一刻起即可免费阅读。

• A publication charge applies to an accepted paper, and the journal points to the publisher's policy and to its waiver scheme.被录用的论文须缴纳出版费用，该刊指明出版方的政策与减免方案。

• Authors keep the copyright of their work, and every article is released under a licence that allows reuse with attribution.作者保留其作品的著作权，每篇文章以允许署名再用的许可发布。

• The journal belongs to a family of titles that share a name, each turned to a different field of treatment.该刊属于一个同名刊物家族，各刊各转向不同的治疗领域。

• The impact figure has eased and then risen, standing at 2.6 for 2023 and reaching 3.3 in the 2025 edition.影响因子先回落而后上升，2023 年为 2.6，2025 年版为 3.3。

• The journal is indexed in the emerging sources citation index, and it is carried in Scopus and in MEDLINE.该刊被新兴资源引文索引收录，并被 Scopus 与 MEDLINE 收录。

• Its papers are also deposited in PubMed and in a public archive, where they are free to read and are preserved.其论文亦存放在 PubMed 与一所公共档案之中，在其中免费阅读并受保存。

• Special collections are assembled around a subject, and the journal gathers work on such themes as precision health technologies.该刊围绕某一题目编成专题合集，汇集诸如精准健康技术一类主题的工作。

Editors

• The journal is led by a body of associate editors rather than by a single named editor-in-chief.该刊由一组副编辑主持，而非由一位具名的主编主持。

• Among them are clinicians and pharmacologists from universities in the United States, Australia, Britain, China and beyond.其中有来自美国、澳大利亚、英国、中国等地大学的临床医生与药理学家。

• A managing editor at the publisher oversees the journal's operation, and a biostatistical editor advises on the analysis of a paper.出版方的一位责任编辑监管该刊运作，另有一位生物统计编辑就论文的分析提供建议。

• The journal sets out the classes of manuscript it takes, along with the length and structure each of them should follow.该刊列明所收稿件的类别，以及各类别应遵循的篇幅与结构。

• Each paper is sent to independent referees, and the review is anonymous on the side of the reviewer.每篇论文送交独立审稿人，评审在审稿人一侧为匿名。

• Authors must declare any competing interest, and the journal states its ethical requirements in full.作者必须声明任何利益冲突，该刊完整说明其伦理要求。

• Work that involves patients is held to the usual standards, and the journal asks that consent and approval be recorded.涉及患者的研究须达到惯常标准，该刊要求记录知情同意与批准情况。

• Where a claim rests on a trial, the journal asks that the registration and the protocol be given.论断若依赖某项试验，该刊要求给出注册信息与试验方案。

• Manuscripts are submitted through the publisher's system, and an enquiry may be made before a paper is written.稿件通过出版方的系统投递，在动笔之前可先行询问。

• Data sharing is encouraged, and the journal points to the publisher's policy that governs it.该刊鼓励数据共享，并指明出版方约束此事的政策。

• The journal is read by cardiologists and by clinical pharmacologists, by general physicians and by health service researchers, and it writes for all of them.该刊的读者既有心脏病医生与临床药理学家，也有全科医生与卫生服务研究者，它为这几类人写作。

• Work that carries a trial result toward a clinic is given room, and the journal asks what the carrying changes.把试验结果带向临床的工作有篇幅可用，该刊追问这一带动改变了什么。

• Studies that report a negative result are taken, since a treatment that failed to help is worth recording.报告阴性结果的研究也在收载之列，因为无助于事的治疗同样值得记录。

• Work on the safety of a drug appears among the subjects, and the journal carries papers on how an adverse effect is found and reported.药物安全性方面的工作列于选题之中，该刊刊载不良效应如何被发现并报告的工作。

• Work on adherence to a treatment is treated, and the journal asks why a patient stops taking a medicine.治疗依从性得到处理，该刊追问患者为何停止服药。

• The journal keeps its reviews distinct from its original reports, and a reader can tell from the rubric which is which.该刊把综述与原始报告区分开来，读者可从栏目看出何者为何者。

• Work on the cost of a treatment is named, and the journal carries papers on what a strategy buys for the money.治疗成本被点名，该刊刊载某种策略以何等花费换得何物的论文。

• Work that links a biomarker to a treatment choice is treated, and the journal asks how the marker guides the decision.把生物标志物与治疗选择相连的工作得到处理，该刊追问标志物如何引导决策。

• Work on the care of an older patient is named, and the journal admits papers on how treatment is adjusted with age.年长患者的照护被点名，该刊收载治疗如何随年龄调整的论文。

• The journal follows the publisher's policy on research integrity, and it records corrections and withdrawals where they arise.该刊遵循出版方的研究诚信政策，出现更正与撤稿时予以记录。